Immunity status and expression of molecular markers (ICAM-1, CD5, CD25, CD95) on lymphocytes of patients with recurrent anterior uveitis complicated by macular edema-Reference-Cited by-同舟云学术

Immunity status and expression of molecular markers (ICAM-1, CD5, CD25, CD95) on lymphocytes of patients with recurrent anterior uveitis complicated by macular edema

Published:2022-12-24 Issue:5 Volume:261 Page:1423-1431
ISSN:0721-832X
Container-title:Graefe's Archive for Clinical and Experimental Ophthalmology
language:en
Short-container-title:Graefes Arch Clin Exp Ophthalmol

Author:

Khramenko Natalia I.,Konovalova Natalia V.,Usov Volodymyr Ya.,Velychko Liudmyla M.,Bogdanova Olexandra V.

Funder

Funding-No funding was received for this research.

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology

Link

https://link.springer.com/content/pdf/10.1007/s00417-022-05938-6.pdf

Reference27 articles.

1. Fardeau C, Champion E, Massamba N, Le Hoang P (2016) Uveitic macular edema. Eye (London, England) 30(10):1277–1292. https://doi.org/10.1038/eye.2016.115

2. Koronis S, Stavrakas P, Balidis M, Kozeis N, Tranos PG (2019) Update in treatment of uveitic macular edema. Drug Des Dev Ther 13:667–680. https://doi.org/10.2147/DDDT.S166092

3. Adán A, Moll-Udina A, Alba-Linero C, Figueroa-Vercellino JP, Llorenç V (2019) Recent progress in the treatment of uveitic macular edema. Expert Rev Ophthalmol 14(4–5):227–236. https://doi.org/10.1080/17469899.2019.1644168

4. de Smet MD (2017) Insights into the physiopathology of inflammatory macular edema. Dev Ophthalmol 58:168–177. https://doi.org/10.1159/000455279

5. Kempen JH, Van Natta ML, Altaweel MM et al (2015) Multicenter Uveitis Steroid Treatment (MUST) trial research group. Factors predicting visual acuity outcome in intermediate, posterior, and panuveitis: the Multicenter Uveitis Steroid Treatment (MUST) trial. Am J Ophthalmol 160(6):1133–1141. https://doi.org/10.1016/j.ajo.2015.09.017